Impact of Curcumin and Pentoxiphylline on Chronic Kidney Disease Patients

• Ethical committee approval has been obtained from Ethics committee of Faculty of Medicine, Alexandria University.
• All participants should agree to take part in this clinical study and will provide informed consent.
• Sixty chronic kidney disease patients will be recruited from the Kidney and Urology Center (KUC) and Alexandria main university hospital (AMUH).

The 60 participants will be randomly assigned into 3 arms.

Group 1 (Control group; n=20): Patients will be treated with standard care only for 6 months. Group 2 (n=20): Patients will be treated with the same standard care plus curcumin capsules 500 mg twice daily for 6 months. Group 3 (n=20): Patients will be treated with the same standard care plus pentoxiphylline 400 mg twice daily for 6 months.

• All patients will be submitted to :

Full patient history and clinical examination. Blood withdrawal in order to conduct lab work.

• Patients demographic data will be recorded with respect to age, weight and other co-morbidities.
• Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results.
• Results, conclusion, discussion and recommendations will be given.

Inclusion criteria

• Age ≥ 18 years old.
• Both sexes.
• Non-hemodialysis CKD patients (Stage III -V)
• Patients matched in the duration of CKD.
• Patients with albumin-to-creatinine ratio ≥ 30 mg/g.
• Patients with serum Potassium < 5 mEq/L

Exclusion criteria

• Patients with elevated level of potassium ≥ 5 mEq/L.
• Patients with cancer.
• Patients with kidney stones and urinary tract infection.
• Patients with bleeding disorder.
• History of drug allergy to study medications.
• Pregnant and breastfeeding women.